髓芯减压植骨自体骨髓间充质干细胞移植治疗早期股骨头缺血性坏死

目的 探讨应用髓芯减压植骨自体骨髓间充质干细胞(BMSCs)移植治疗早期股骨头缺血性坏死(ANFH)的疗效.方法 对26例早期ANFH采用髓芯减压植骨自体BMSCs移植治疗.结果 随访6～30个月,患者疼痛明显缓解,采用Harris髋关节功能评分,术前平均(51.6±4.86)分,术后为(93.8±7.36)分,比较差...     

动脉灌注髓芯减压干细胞移植治疗股骨头坏死

目的评价动脉灌注加股骨头髓芯减压后注射干细胞治疗成人股骨头缺血性坏死的疗效。方法对30例成人股骨头缺血性坏死（ARCO分期ⅠA～ⅢA期）分别采用单纯动脉灌注、动脉灌注加股骨头髓芯减压、动脉灌注加股骨头髓芯减压后行干细胞移植三种方法治疗。术后采用髋关节Harris评分及影像学（主要为MRI）情况评定疗效。结果动脉灌注加股骨头髓芯减压后注射干细胞较另外两组在MRI表现上有明显差异（P〈0．05）。结论通过对早期股骨头缺血性坏死进行血管灌注、股骨头髓芯减压及自体骨髓干细胞注射的治疗,可以延缓或阻止股骨头缺血坏死、塌陷、变形的病理过程。     

髓芯减压并自体干细胞移植治疗早期股骨头坏死14例报告

目的分析髓芯减压并自体骨髓间充质干细胞移植治疗早期股骨头缺血性坏死的疗效。方法根据ARCO分期,随机选取单侧股骨头坏死早期病例14例,其中Ⅰ期7例,Ⅱ期4例,Ⅲ期3例,实施髓芯减压并自体骨髓间充质干细胞移植的治疗办法。结果经随访,患髋Har-ris评分术后1年（平均79.56）较术前（平均56.23）增加显著。结论对早期股骨头坏死的患者,髓芯减压并自体骨髓间充质干细胞移植是一种有效的手术治疗方法。     

髓芯减压植骨并自体骨髓间质干细胞移植治疗股骨头坏死手术配合

对5例股骨头缺血性坏死患者采用髓芯减压并自体骨髓间质干细胞移植治疗。结果5例均于术后3周后下床活动，髋关节疼痛完全消失。3个月后复查示，50％股骨头死骨成活，HHS评分≥95分。提示自体骨髓间质干细胞移植治疗股骨头缺血性坏死创伤小、疗效好，早期股骨头坏死患者可恢复髋关节功能。手术室严格执行消毒隔离制度，巡回护士和器械护士熟悉手术配合步骤，充分准备物品，严格无菌操作，控制术中感染，才能确保手术顺利完成。     

自体骨髓干细胞移植治疗激素性股骨头坏死

目的观察自体骨髓干细胞移植治疗激素性股骨头坏死的临床效果。方法52例激素性股骨头缺血性坏死患者经使用rhG-CSF进行骨髓干细胞动员后,第2天进行骨髓干细胞采集,在数字减影血管造影术（DSA）下行股动脉穿刺,导管超选择至闭孔动脉及旋股内外侧动脉,将干细胞悬液缓慢匀速注入动脉内;干细胞移植后随访观察患者髋关节疼痛程度、性质及持续时间变化,行走间距及步态变化,髋关节外展及内旋功能变化;6个月后行股骨头供血动脉造影术。结果52例患者随访12个月,髋关节疼痛有不同程度缓解67％,关节功能改善29．7％,行走间距延长32．5％。干细胞移植术后6个月,10例患者行股骨头供血动脉数字减影血管造影检查,均显示旋股内动脉,旋股外动脉及闭孔动脉管径增粗,新生血管增多,血流速度增快,与移植前血管造影相比较,股骨头血液供应明显改善。治疗中均未发生严重的并发症和不良反应。结论自体骨髓干细胞移植治疗激素性股骨头坏死方法简便,安全有效,适合Ⅰ-Ⅲ期早、中期股骨头坏死的患者。     

髓芯减压植骨并自体骨髓间质干细胞移植治疗股骨头坏死手术配合

对5例股骨头缺血性坏死患者采用髓芯减压并自体骨髓问质干细胞移植治疗.结果 5例均于术后3周后下床活动.髋关节疼痛完全消失.3个月后复查示,50%股骨头死骨成活,HHS评分≥95分.提示自体骨髓问质干细胞移植治疗股骨头缺血性坏死创伤小、疗效好,早期股骨头坏死患者可恢复髋关节功能.手术室严格执行消毒隔离制度,巡回护士和器械护士熟悉手术配合步骤,充分准备物品,严格无菌操作,控制术中感染,才能确保手术顺利完成.     

计算机导航辅助髓芯减压自体骨髓移植治疗早期股骨头坏死

目的探讨计算机导航辅助多孔髓芯减压自体骨髓移植治疗早期(ARCOⅠ、Ⅱ期)股骨头坏死的临床疗效。方法计算机导航辅助多孔髓芯减压自体骨髓移植治疗18例ARCOⅠ、Ⅱ期股骨头坏死(21髋)。末次随访时采用Harris评分标准对手术疗效进行评价。结果患者均获得24个月随访。末次随访时采用Harris评分评价疗效:优16髋,良4髋,可1髋。结论计算机导航辅助多孔髓芯减压自体骨髓移植治疗早期股骨头坏死具有改善功能、延缓病程的作用。     

骨髓基质干细胞移植治疗兔股骨头缺血性坏死的实验研究

[目的]探讨骨髓基质干细胞移植对股骨头缺血性坏死的治疗作用和修复机理，为临床应用提供依据。[方法]24只新西兰大白兔随机分为两组，A组为髓芯减压组，B组为干细胞移植组。采用液氮冷冻法造模。A组钻孔后植入空白明胶海绵，B组钻孔后植入复合有骨髓基质干细胞的明胶海绵。术后每组分别于2、4、6、8周各处死3只动物，做X线及组织学检查。[结果]（1）X线结果：2周时A、B组钻孔区均呈低密度，4周时A组钻孔边缘密度增加，B组整个钻孔区密度增加，8周时A组钻孔区均呈低密度，边缘形成硬化线，B组钻孔区形成骨小梁结构。（2）组织学结果：2周时A组钻孔区出现少许炎症细胞，边缘出现较多成骨细胞并有骨组织形成，至8周时，钻孔区内形成骨髓组织，只在边缘形成骨小梁结构。2周时B组钻孔区有大量的成骨细胞，边缘有较多骨组织形成，4周时钻孔区内充满新生骨小梁结构，8周时钻孔区内骨小梁成熟，小梁有骨髓组织填充。[结论]骨髓基质干细胞对兔股骨头缺血性坏死有良好的修复作用。     

髓芯减压联合自体骨髓干细胞移植治疗早中期股骨头坏死近期疗效

目的 观察髓芯减压联合自体骨髓于细胞移植治疗早中期股骨头坏死的临床疗效.方法 笔者自2004年1月～2008年11月选取符合国际骨循环研究会(ARCO)骨坏死分期标准共41例(55髋),经过自体骨髓干细胞采集、分离、髓芯减压及干细胞移植.随访观察患髋疼痛缓解程度,手术前后Harris评分及影像学进展情况.结果 35例(...     

髓芯减压联合自体骨髓干细胞移植治疗股骨头坏死的早期临床观察

目的 观察髓芯减压植骨联合自体骨髓干细胞移植治疗早期股骨头坏死的临床疗效.方法 根据国际骨循环研究学会(Association Research Circulation Osseous,ARCO)骨坏死分期标准,选取Ⅰ、Ⅱ期股骨头坏死32例(39髋),治疗组18例(24髋),对照组14例(15髋).治疗组经过自体骨髓干细胞采集、分离、髓芯减压后,骨髓干细胞和松质骨混合植入;对照组行髓芯减压松质骨植入.结果 所有患者均获18个月的随访,行Harris评分和影像学检查.(1)髋关节Harris评分:治疗组由(55.90±9.71)分升至(81.86±7.95)分,优良率为87.5%;而对照组由(56.69±8.32)分升至(68.14±8.65)分,优良率为60.0%,两组比较差异有统计学意义(P<0.01);(2)髋关节影像学检查:治疗组仅1例(1髋)发展为Ⅲ期塌陷,而对照组2例(2髋)发展为Ⅲ期塌陷;MRI测得坏死面积百分比,治疗组由31.88%±7.59%降至13.20%±9.56%,而对照组由32.64%±6.32%降至21.18%±8.83%,两组比较差异有统计学意义(P<0.05).结论 髓芯减压植骨联合自体骨髓干细胞移植治疗早期股骨头坏死是一种安全、有效的方法,但还需要大样本临床试验及长期随访以进一步验证.     

Core Decompression with Local Administration of Zoledronate and Enriched Bone Marrow Mononuclear Cells for Treatment of Non‐Traumatic Osteonecrosis of Femoral Head

ObjectiveTo investigate the efficacy and safety of core decompression (CD) with local administration of zoledronate and enriched bone marrow mononuclear cells (BMMCS) for the treatment of non‐traumatic osteonecrosis of femoral head (ONFH).MethodsA total of 17 patients (30 hips) diagnosed with stage II and III ONFH according to the 2019 revised Association for Research on Osseous Circulation (ARCO) staging criteria from 2012 to 2014 were retrospectively reviewed. The patients received the following therapy: the BMMCs and zoledronate were injected into the necrotic zone, respectively, along with CD. The mean age of the patients was 36.8 years; 14 were men and three were women. All patients included had non‐traumatic ONFH and a minimum follow‐up of 5 years, which ended when total hip arthroplasty (THA) was performed. Imaging modalities, including plain radiography, computed tomography (CT), and magnetic resonance imaging (MRI) were taken pre‐ and postoperatively. Harris hip score (HHS) was used to evaluate the functional outcomes of femoral head necrosis. Kaplan–Meier analysis was adopted to determine the probability of survivorship with THA as the end point in this series of patients. The correlation between radiological progression or THA and related risk factors were further analyzed. All complications were recorded.ResultsWith THA as the follow‐up endpoint, All patients were followed up for an average of 69.1 ± 20.5 months (range, 18–95 months). Preoperative imaging found six hips (20%) at ARCO stage II, 14 hips (46.7%) at stage IIIA, 10 hips (33.3%) at stage IIIB. Fourteen hips (46.7%) shown progression radiologically, while six hips (20%) underwent TKA among these patients with hip preservation. The cumulative survival was 80% (95% CI, 0.608–905) at 5 years with THA as the end point. HHS improved from 63.3 ± 8.7 preoperatively to 74.6 ± 20.6 postoperatively (P = 0.000). Radiological progression was found to be associated with ARCO stage, Japanese Investigation Committee (JIC) type, and corticosteroid exposure (P = 0.047; P = 0.012; P = 0.031). However, no correlation was found between conversion to THA and the known risk factors. No major complication was reported, with only four patients complaining about general weakness and muscle soreness, and all disappeared within 2–3 days.ConclusionsThe novel treatment modality could relieve pain, delay the progression of collapse, which might be an effective and safe method for hip preservation of early and mid‐term ONFH. However, the effect of this method may be related to ARCO stage, JIC type, and corticosteroid exposure.     

Culture-Expanded Autologous Adipose-Derived Mesenchymal Stem Cell Treatment for Osteonecrosis of the Femoral Head

BackgroudOutcomes of traditional treatment for osteonecrosis of the femoral head (ONFH) are not always satisfactory. Hence, cell-supplementation therapy has been attempted to facilitate necrotic-tissue regeneration. Adipose-derived mesenchymal stem cell (ADMSC) transplantation is potentially advantageous over bone marrow-derived MSC implantation, but its outcomes for ONFH remain unclear. The aim of this study was to determine 2-year radiological and clinical outcomes of culture-expanded autologous ADMSC implantation for ONFH.MethodsEighteen hips with necrotic lesions involving ≥ 30% of the femoral head were included. ADMSCs were harvested by liposuction and culture expanded for 3 passages over 3 weeks. With a 6-mm single drilling, ADMSCs were implanted into the necrotic zone. All patients underwent magnetic resonance imaging (MRI), single-photon emission computed tomography/computed tomography (SPECT/CT) at screening and 6 months, 12 months, and 24 months postoperatively. The primary outcome was the change in the size of necrotic area on MRI. Secondary outcomes were changes in clinical scores and radioisotope uptake on SPECT/CT. Conversion total hip arthroplasty (THA) was defined as the endpoint.ResultsPreoperatively, the necrotic lesion extent was 63.0% (38.4%–96.7%) of the femoral head. The mean Harris hip score was 89.2, the University of California at Los Angeles (UCLA) score was 5.6, and Western Ontario and McMaster Universities Arthritis index (WOMAC) was 79.4. Three patients underwent THA and 1 patient died in an accident. Finally, 11 patients (14 hips) were available for ≥ 2-year follow-up. At the last follow-up, no surgery-related complications occurred, and 14 of 17 hips (82%) were able to perform daily activities without THA requirement. There was no significant decrease in lesion size between any 2 intervals on MRI. However, widening of high signal intensity bands on T2-weighted images inside the necrotic lesion was observed in 9 of 14 hips (64%); 11 of 14 hips (79%) showed increased vascularity on SPECT/CT at 2 years postoperatively. No significant differences were observed between preoperative and 24-month mean Harris hip score (89.2 vs. 88.6), WOMAC (79.4 vs. 75.7), and UCLA score (5.6 vs. 6.2).ConclusionsOur outcomes suggest that culture-expanded ADMSC implantation is a viable option for ONFH treatment without adverse events.     

关节镜下髓芯减压骨膜骨颗粒移植治疗股骨头坏死

目的观察关节镜下髓芯减压骨膜骨颗粒坚实充填移植治疗青壮年股骨头坏死的临床效果。方法对25例(36髋)股骨头坏死于X线机透视下在股骨大转子下经股骨颈打1条通向病灶的骨隧道,经该隧道放置关节镜并行病灶清除;用约3mm×3mm×3mm的自体髂骨颗粒与1mm3的胫前骨膜颗粒的混凝物坚实充填股骨头骨洞。参照百分法进行疗效分析。结果X线片多显示较好的骨修复,疼痛及功能多改善明显。总优良率为72.2%,其中Ⅰ期(3髋/3髋)、Ⅱ期(15髋/19髋)、ⅢA和ⅢB期(7髋/11髋)患者治疗效果较好,ⅢC期较差(1髋/3髋)。结论初步观察该方法可用于治疗Ⅰ期、Ⅱ期、ⅢA期、ⅢB期青壮年股骨头坏死患者。     

髓芯减压BMP植入治疗股骨头坏死的血流量及病理改变

目的：研究股骨头坏死的早期治疗方法。方法：选取6月龄健康新西兰白兔42只，随机分组，注射激素制作股骨头坏死模型，行髓芯减压加植骨、髓芯减压植骨加BMP治疗，SPECT观察血流量的改变。结果：随着激素应用时间的延长，股骨头局部核素吸收量逐渐减少。应用激素第4周血流量降至正常的72%，6周为69%，8周为56%。髓芯减压术后2周恢复至正常的82%，4周时恢复正常。髓芯减压加BMP骨泥治疗组4周后镜下改变为大量新生骨形成，爬行替代坏死的骨小梁，且在新生骨周围有大量的新生血管形成。结论：髓芯减压术能改善坏死股骨头的血运，骨诱导蛋白（BMP）对坏死的股骨头具有骨诱导作用，能刺激新生骨的形成，爬行替代坏死的骨小梁，而且能刺激新生血管形成。     

骨髓源性干细胞移植肺再生的研究进展

由于肺组织无再生能力,肺疾病的治疗成为棘手的问题。目前认为骨髓源性干细胞（bone marrow derived stem cell）能定向分化成为肺组织细胞,将骨髓源性干细胞移植入损伤的肺组织,通过诱导剂使其向肺泡上皮细胞分化,从而产生肺泡组织。这是一种很有前途的治疗手段,但目前尚处于研究的初级阶段。现对骨髓干细胞移植在各种肺疾病模型中的应用进行综述。     

骨髓间充质干细胞自体移植治疗心肌梗死的实验研究

目的探讨兔骨髓间充质干细胞(MSCs)移植至缺血心肌后的增殖分化情况,对缺血心肌细胞的修复重建能力及心功能改善情况。方法将20只新西兰白兔随机分为骨髓间充质干细胞移植组(MSCs组,n=10)和对照组(n=10),采用结扎冠状动脉左前降支(LAD)制备心肌梗死模型,2周后分别将Dil标记的1×106个细胞悬液400μl或等量L-DMEM培养基用微量注射器注入梗死灶边缘,于建模前、建模后2周、细胞移植后2、4周采用多普勒超声心动图检测左心室收缩期末内径(LVESD)、左心室舒张期末内径(LVEDD),计算左心室射血分数(LVEF)、左心室短轴缩短率(LVFS)评价心脏收缩功能,同时进行心肌声学造影评价心肌组织的血流灌注情况。细胞移植后8周处死所有动物,病理学检查移植细胞在梗死区的生长状况。结果多普勒超声心动图检测结果显示:两组动物建模前、建模后2周LVEF、LVFS差异无统计学意义(0.72±0.08vs.0.71±0.04,0.56±0.11vs.0.55±0.09;0.35±0.06vs.0.35±0.04,0.24±0.08vs.0.23±0.03,P>0.05),细胞移植后2、4周MSCs组LVEF、LVFS值均明显高于对照组(0.71±0.05vs.0.60±0.05,0.72±0.07vs.0.62±0.08;0.34±0.03vs.0.29±0.01,0.35±0.06vs.0.27±0.05,P<0.05);病理学检查见自体MSCs移植8周后存活于梗死心肌中,表达肌细胞特异性标志,并且能显著增加瘢痕区毛细血管密度(38.6±7.6/mm2vs.21.4±3.9/mm2,P<0.05),心肌声学造影亦显示梗死局部血流灌注MSCs组较对照组明显改善。结论自体MSCs移植缺血心肌中可向心肌细胞分化,增加心肌血流灌注,改善心脏收缩功能。     

经粗隆下股骨头倒V形钻孔加丹参灌注治疗股骨头骨坏死

从1987年起我们设计并运用股骨头倒V形钻孔加丹参灌注治疗成人股骨头坏死54例,经过2～8.5年临床观察显示,该方法疗效明显,总优良率达81％,Ⅰ～Ⅱ期优良率达94％,该方法与同类其它方法比较还具有手术难度小,创伤小,对患者机体负影响小等优点。适应于Ⅰ～Ⅲ期的股骨头无菌性坏死。     

骨髓干细胞和脂肪干细胞对纳米磁铁颗粒的摄取性能研究

目的 研究两种纳米磁性氧化铁颗粒分别与骨髓干细胞(Bone marrow stem cells,BMSCs)和脂肪干细胞(Adipose derived stem cells,ADSCs)共培养时细胞对磁铁颗粒的摄取情况,以初步探讨其作为磁共振成像(MRI)对比剂去标记组织工程种子细胞而进行MRI示踪的可行性.方法 制备粒径为6 nm的Fe3O4磁性颗粒及经聚L-乳酸(PLLA)表面修饰的Fe3O4磁性颗粒(200 nm),分别在细胞接种时及接种后24小时两种方式加入.使用电感耦合等离子体质谱(ICP-OES)检测细胞对铁颗粒的摄取量.结果 细胞对铁颗粒的摄取量受纳米磁铁颗粒的种类,加入方式和细胞类型的影响.BMSCs和ADSCs对6 nm粒径磁铁颗粒的摄取量显著高于对200 nm铁颗粒的摄取量,而ADSCs摄取的量又高于BMSCs.结论 6 nm粒径的磁性氧化铁颗粒可以较好的被BMSCs和ADSCs吸收,具有良好的生物相容性,有望成为组织工程种子细胞的标记物来进行MRI示踪.